Revolutionary therapeutic treatment for stopping progression of Parkinson's disease

Project Information

ReTreatPD

Grant agreement ID: 190132320

DOI

10.3030/190132320

Project closed

EC signature date 7 April 2023

Start date 1 May 2023

End date 30 April 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 4 083 500,00

EU contribution

€ 2 500 000,00

Coordinated by

HERANTIS PHARMA OYJ
Finland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (1)

Report on communication activities

Publications

Peer reviewed articles (7)

Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson’s disease

Author(s): Kulesskaya, Natalia; Holmström, Kira M.; Huttunen, Henri J.
Published in: Neural regeneration research, ISSN 1876-7958
Publisher: Elsevier
DOI: 10.4103/NRR.NRR-D-24-00187OPENPAP

Progress in development of disease-modifying treatments in Parkinson's Disease

Author(s): Henri Huttunen
Published in: Open Access Government, Issue 39, 2023, ISSN 2516-3817
Publisher: Adjacent Digital Politics Ltd
DOI: 10.56367/OAG-039-10888

Structural basis of CDNF interaction with the UPR regulator GRP78

Author(s): Melissa A. Graewert, Maria Volkova, Klara Jonasson, Juha A. E. Määttä, Tobias Gräwert, Samara Mamidi, Natalia Kulesskaya, Johan Evenäs, Richard E. Johnsson, Dmitri Svergun, Arnab Bhattacharjee, Henri J. Huttunen
Published in: Nature Communications, Issue 15, 2024, ISSN 2041-1723
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41467-024-52478-0

Exploring HER-096: A novel approach to Parkinson’s Disease

Author(s): Huttunen H
Published in: Open Access Government, ISSN 2631-3200
Publisher: Open Access Government
DOI: 10.56367/OAG-041-11195

HER-096 is a CDNF-derived brain-penetrating peptidomimetic that protects dopaminergic neurons in a mouse synucleinopathy model of Parkinson's disease

Author(s): Natalia Kulesskaya, Arnab Bhattacharjee, Kira M Holmström, Päivi Vuorio, Alexandre Henriques, Noëlle Callizot, Henri J Huttunen
Published in: Cell Chemical Biology, ISSN 2451-9448
Publisher: Elsevier Ltd
DOI: 10.1016/J.CHEMBIOL.2023.11.005

Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop

Author(s): Roger A Barker, Mart Saarma, Clive N Svendsen, Catherine Morgan, Alan Whone, Massimo S Fiandaca, Matthias Luz, Krystof S Bankiewicz, Brian Fiske, Lyndsey Isaacs, Arthur Roach, Thomas Phipps, Jeffrey H Kordower, Emma L Lane, Henri J Huttunen, Aideen Sullivan, Gerard O’Keeffe, Valeria Yartseva, Howard Federoff
Published in: Journal of Parkinson’s Disease, Issue 14, 2025, ISSN 1877-7171
Publisher: SAGE Publications
DOI: 10.1177/1877718X241301041

Symptomatic vs. Disease-modifying treatments in neurological diseases: Where next?

Author(s): Henri Huttunen
Published in: Open Access Government, Issue 43, 2024, ISSN 2516-3817
Publisher: Adjacent Digital Politics Ltd
DOI: 10.56367/OAG-043-11195